Health Care • Biotechnology: Pharmaceutical Preparations
$75.00 ▲ +0.05
(+0.06%)
MKT CAP: $14.60B • VOL: 3.10M
52W L $60 52W H $93
BBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $502.1M | $221.9M | $9.3M |
| YoY Revenue Growth % | +126.3% | +2285.3% | — |
| Gross Profit | $481.1M | $218.0M | — |
| Gross Margin % | 95.8% | 98.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$523.4M | -$593.0M | -$607.4M |
| Operating Margin % | -104.2% | -267.2% | -6528.8% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | -$522.5M | -$592.2M | -$607.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$445.9M | -$520.7M | -$527.7M |
| Capital Expenditures (CapEx) | $1.1M | $933.0K | $418.6K |
| Free Cash Flow (FCF) | -$447.0M | -$521.7M | -$528.1M |
| FCF Margin % | -89.0% | -235.1% | -5677.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -10.4% |
| Cash & Short-Term Equivalents | $570.1M | $681.1M | — |
| Total Debt (Short + Long Term) | $1.36B | $437.3M | $1.78B |
| Total Stockholders' Equity | -$2.09B | -$1.47B | $3.65B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BBIO.